1345012-46-5

Upstream product

• 6146-52-7 5-nitroindole 
• 98-09-9 benzenesulfonyl chloride 
• 519056-50-9 5-nitro-1-(phenylsulfonyl)indoline 
• 124400-51-7 5-nitro-1-(phenylsulfonyl)-1H-indole 
• 81114-41-2 1-benzenesulfonyl-2,3-dihydro-1H-indole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 124400-52-8 1-Benzenesulfonyl-1H-indol-5-yl amine 
• 496-15-1 1-indoline 

Downstream Products

• 1345012-48-7 tert-butyl 2-(4-methylpiperazin-1-carbonyl)-1-(phenylsulfonyl)-1H-indol-5-ylcarbamate 
• 1345012-49-8 (5-amino-1-(phenylsulfonyl)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone 
• 1345012-51-2 (5-(1-((2-((4-methoxybenzyl)(pyridin-2-yl)amino)ethyl)(methyl)amino)propan-2-ylamino)-1H-indol-2-yl)(4-methylpiperazin-1-yl)methanone 
• 1345012-47-6 5-(tert-butoxycarbonylamino)-1-(phenylsulfonyl)-1H-indole-2-carboxylic acid 

Relevant academic research and scientific papers

A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia

Mutants of the FLT3 receptor tyrosine kinase (RTK) with duplications in the juxtamembrane domain (FLT3-ITD) act as drivers of acute myeloid leukemia (AML). Potent tyrosine kinase inhibitors (TKi) of FLT3-ITD entered clinical trials and showed a promising,

SYNTHESIS, PHARMACOLOGY AND USE OF NEW AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) FLT3 INHIBITORS

The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the com

Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH 1R, but low affinity to hH4R

In literature, a synergism between histamine H1 and H 4 receptor is discussed. Furthermore, it was shown, that the combined application of mepyramine, a H1 antagonist and JNJ7777120, a H 4 receptor ligand leads to a synergistic effect in the acute murine asthma model. Thus, the aim of this study was to develop new hybrid ligands, containing one H1 and one H4 pharmacophor, connected by an appropriate spacer, in order to address both, H1R and H 4R. Within this study, we synthesized nine hybrid compounds, which were pharmacologically characterized at hH1R and hH4R. The new compounds revealed (high) affinity to hH1R, but showed only low affinity to hH4R. Additionally, we performed molecular dynamic studies for some selected compounds at hH1R, in order to obtain information about the binding mode of these compounds on molecular level.